RESUMEN

BACKGROUND: Solitary drinking is a risky drinking pattern associated with increased substance use and psychosocial problems. However, very little is known regarding the associations between drinking alone and broader health status and behaviors. PURPOSE: Accordingly, this study examined the relationship between health metrics and solitary drinking among individuals who currently drink (N = 99, 46.46% female, 88.89% White). METHODS: U.S. participants between 21 and 40 years old were recruited. Measures included self-reported diet, physical activity, sleep, cannabis use, general and solitary alcohol use, and objective anthropomorphic measures (e.g., body mass index [BMI]) using data from both a baseline appointment and 30 days of daily diary responses. Adjusting for general alcohol use, age, and gender, associations at baseline were assessed through regression analyses, while daily data were analyzed via mixed effects models. RESULTS: Several health measures were associated with solitary drinking. Specifically, solitary drinking was related to consuming fewer servings of fruits and vegetables and greater quantities of alcohol based on daily data. Baseline data showed an association between solitary drinking and higher BMIs, poorer sleep quality, greater sugar consumption, and hazardous drinking. CONCLUSIONS: These findings suggest that beyond substance and psychosocial problems associated with solitary drinking, this drinking behavior may be a warning sign for health risks and, subsequently, broader health problems.

Associations between health metrics and lifetime solitary drinking were examined among individuals who currently drink alcohol (N = 99, 46.46% female, 88.89% White). Solitary drinking was related to less fruit and vegetable consumption, greater sugar consumption, more hazardous drinking, poorer sleep quality, and higher body mass index. Findings suggest that solitary drinking may be a warning sign for health risks and, subsequently, broader health problems.

RESUMEN

Objective: Cannabis has been touted for a host of pharmacological and therapeutic effects and users commonly report reduced symptoms of physical and mental health conditions, including anxiety, depression, and chronic pain. While there is existing empirical evidence supporting these effects of cannabis use, little is known about the extent to which these effects result from pharmacological versus expectancy factors. We evaluated the associations between participants' cannabis expectancies and their acute self-reported reactions after using legal market forms of cannabis with varying levels of cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) in three domains: anxiety, depression, and pain. Methods: Fifty-five flower and 101 edible cannabis users were randomly assigned and asked to purchase at a local dispensary one of three products containing varying levels of CBD and THC. Participants completed a baseline assessment where they reported expectancies about general health effects of cannabis use and an experimental mobile laboratory assessment where they administered their assigned products. Edible users also reported their domain-specific expectancies about cannabis use in improving anxiety, depression, and pain. Following administration, participants completed acute indicators of anxiety, depression, and pain operationalized through subjective acute tension, elation, and a single-item measure of pain. Results: Among flower users, more positive expectancies for cannabis to improve general health were correlated with greater reductions in tension at acute post-use. This finding was replicated among edible users. Unlike flower users, more positive expectancies for cannabis to improve general health were also correlated with greater increases in elation and greater reductions in pain among edible users. More positive expectancies for cannabis to improve depression and pain were also correlated with greater increases in elation and greater reductions in pain, respectively, among edible users. Conclusions: Cannabis users' expectancies significantly impacted some of the acute subjective effects of legal market cannabis products. Among both flower and edible users, consistent, significant expectancy effects were found. Results were consistent with prior findings and demonstrate the need to measure and control pre-existing expectancies in future research that involves cannabis administration. Clinical trial registration number: NCT03522103.